Experimental study on long-term exposure to a biocompatible, hypertonic, pyruvate-buffered dialysis solution.

Area of Science:

• Nephrology
• Biomaterials Science
• Peritoneal Dialysis

Background:

• Chronic exposure to glucose and its degradation products (GDPs) in dialysis solutions contributes to peritoneal neoangiogenesis and fibrosis, potentially causing encapsulating peritoneal sclerosis (EPS).
• High lactate concentrations in dialysis solutions may exacerbate glucose toxicity by inducing pseudohypoxia, stimulating growth factor production.

Purpose of the Study:

• To evaluate the long-term effects of a novel pyruvate-buffered solution (PYRAGG) containing amino acids, glycerol, and glucose on peritoneal function and morphology.
• To compare the biocompatibility of PYRAGG with conventional heat-sterilized (LH) and filter-sterilized (LF) glucose/lactate solutions.

Main Methods:

• Rats underwent daily 20-week exposure to PYRAGG, LH, or LF dialysis solutions.
• Peritoneal function tests were conducted, and peritoneal tissue was analyzed post-exposure.

Main Results:

• Peritoneal solute and fluid transport remained similar across all groups after 20 weeks.
• The LH group exhibited the most pronounced fibrosis, attributed to GDPs.
• The PYRAGG group showed a significant 59% reduction in omental vessels compared to LH, indicating reduced glucose effects.

Conclusions:

• PYRAGG demonstrated superior biocompatibility compared to filter-sterilized glucose/lactate solutions, without inducing significant peritoneal abnormalities or altering transport characteristics.
• PYRAGG-like solutions hold promise for reducing the incidence of encapsulating peritoneal sclerosis (EPS).